Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). Additionally we are shipping Fanconi Anemia Group A Protein Proteins (4) and Fanconi Anemia Group A Protein Kits (2) and many more products for this protein.
Showing 10 out of 104 products:
Human Polyclonal FANCA Primary Antibody for IP, WB - ABIN5665644
Hicks, Chute, Paulsen, Ragland, Howlett, Guéranger, Glover, Canman: Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links. in Molecular and cellular biology 2010
Show all 3 Pubmed References
Human Polyclonal FANCA Primary Antibody for WB - ABIN251002
Park, Ciccone, Beck, Hwang, Freie, Clapp, Lee: Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins. in The Journal of biological chemistry 2004
Human Polyclonal FANCA Primary Antibody for ELISA, ICC - ABIN4309986
Huard, Tremblay, Magron, Lévesque, Carreau: The Fanconi anemia pathway has a dual function in Dickkopf-1 transcriptional repression. in Proceedings of the National Academy of Sciences of the United States of America 2014
the current study was the first to report a promoter region variation in the FANCA gene among women with breast cancer in Iran. The results of the present study confirmed the allelic variants in the FANCA promoter region as a tumor suppressor gene.
we show that although FANCA S1088F protein properly localizes to the nucleus, it alters FANC complex function, enhances sensitivity to DNA damaging agents, and sensitizes cells to PARP (show COL11A2 Antibodies) inhibitors in vitro and in vivo.
FancA amplification and overexpression appear to be crucial for radiotherapeutic failure in head and neck squamous cell carcinomas.
High resolution melting curve analysis was used to screen FANCA, and LinReg software version 1.7 was utilized for analysis of expression. RESULTS: In total, six sequence alterations were identified, which included two stop codons, two frames-shift mutations, one large deletion and one amino acid exchange. FANCA expression was downregulated in patients who had sequence alterations.
Results identified homozygous mutations in FANCA and FANCP/SLX4 (show BTBD12 Antibodies) genes, both located on chromosome 16, were the affected recessive FA genes in three and one family respectively. Genotyping with short tandem repeat markers and SNP arrays revealed uniparental disomy of the entire mutation-carrying chromosome 16 in all four patients.
Using human and murine cells defective in FANCD2 (show FANCD2 Antibodies) or FANCA and primary bone marrow cells derived from FANCD2 (show FANCD2 Antibodies) deficient mice, we show that the FA pathway removes R loops and that many DNA breaks accumulated in FA cells are R loop-dependent.
FANCA safeguards interphase and mitosis during hematopoiesis
The I939S point mutation prevented binding to the FAAP20 subunit of the FA core complex, caused SUMOylation at K921, RNF4 (show RNF4 Antibodies)-mediated polyubiquitination and degradation.
A frameshifting mutation and a truncating mutation of FANCA are associated with Fanconi anemia (show PALB2 Antibodies).
Proliferation is compromised in FANCA-deficient pluripotent embryonic stem cells.
study indicates that Fanca expression during endomitosis is crucial for normal megakaryopoiesis and platelet production.
Data show that Fanconi anemia complementation group A Fanca is required for the induction of transition mutations at A/T residues during somatic hypermutation (SHM (show CNTNAP1 Antibodies)) and immunoglobulin (Ig) class switch recombination (CSR (show SCARA3 Antibodies)).
CD25 (show IL2RA Antibodies)(+)Foxp3 (show FOXP3 Antibodies)(+) Tregs of Fanca(-/-) or Fancd2 (show FANCD2 Antibodies)(-/-) mice were less efficient in suppressing the production of GVHD-associated inflammatory cytokines.
null mutations in Fanca or Fancg (show FANCG Antibodies) are fully epistatic
genetic diversity in FANCA, FANCC (show FANCC Antibodies) and FANCL (show FANCL Antibodies) does not support an association of these genes with cervical cancer susceptibility in the Swedish population.
The results support a model where both FANCA and FANCC (show FANCC Antibodies) are part of a multi-protein nuclear FA complex with identical function in cellular responses to DNA damage and germ cell survival.
To study the in vivo role of the FA group A gene (Fanca), gene-targeting techniques were used to generate Fanca(tm1Hsc) mice in which Fanca exons 1-6 were replaced by a beta (show SUCLA2 Antibodies)-galactosidase (show GLB1 Antibodies) reporter construct.
GnRH (show GNRH1 Antibodies) induced a rapid, transient increase in Fanca mRNA.
Fanca protein as an integral component in the early step of homologous repair of DNA double-strand brearks thereby minimizing the genomic instability.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity\; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group A. Alternative splicing results in multiple transcript variants encoding different isoforms. Mutations in this gene are the most common cause of Fanconi anemia.
Fanconi anemia group A protein
, Fanconi anemia, complementation group H
, Fanconi anemia, type 1
, Fanconi anemia group A protein homolog